Europe’s CHMP Clears Sofosbuvir, Dolutegravir And Dalamanid
This article was originally published in The Pink Sheet Daily
Executive Summary
As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.